Clinical effect of calcium dibutyryladenosine cyclophosphate injection combined with levocarnitine in the treatment of heart failure
10.3760/cma.j.issn.1008-6706.2019.05.013
- VernacularTitle:二丁酰环磷腺苷钙联合左卡尼丁辅助治疗心力衰竭的临床观察
- Author:
Dongmei ZHANG
1
Author Information
1. 烟台市烟台山医院心导管室 264008
- Keywords:
Heart failure;
Cardiac output;
Natriuretic peptide;
brain;
Uric acid;
Dibuty cyclophosphate calcium;
Left carnitine
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(5):564-567
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of calcium dibutyryladenosine cyclophosphate injection combined with levocarnitine in the treatment of chronic heart failure (CHF).Methods From February 2016 to February 2017,80 patients with CHF were randomly divided into observation group and control group according to the digital table,with 40 cases in each group.The control group was treated with calcium dibutyryladenosine cyclophosphate injection.The observation group was treated with calcium dibutyryladenosine cyclophosphate and levocarnitine injection.The patients were treated for 2 weeks.The changes in cardiac function indicators before and after treatment,left ventricular ejection fraction (LVEF),cardiac output (CO),each stroke volume index (CI),N-terminal B-type natriuretic peptide (N-proBNP) and blood uric acid (UA) were observed.Resuts The cardiac function of two groups was improved after treatment.The LVEF,CO,CI in the two groups were increased after treatment.The LVEF,CO,CI in the observation group after treatment were (59.95 ± 4.17) ％,(6.24 ± 0.22) L,(2.86 ± 0.10) L · min-1 · (m2)-1,respectively,which in the control group were (49.05 ± 5.72) ％,(4.83 ± 0.44) L,(2.25 ± 0.16) L · min-1 · (m2)-1,respectively,the differences were statistically significant (t =2.26,18.18,5.78,P =0.03,0.00,0.01).After treatment,the N-proBNP and UA levels in the two groups were decreased (all P ＜ 0.05).The N-proBNP and UA levels in the observation group were (207.78 ± 42.35) pg/mL,(268.50 ± 14.30) μmol/L,respectively,which in the control group were (498.88 ± 72.06) pg/mL,(422.75 ± 46.48) μ mol/L,respectively,the differences between the two groups were significant (t =-22.03,20.06,P =0.00,0.00).Conclusion Calcium dibutyryladenosine cyclophosphate combined with levocarnitine in the treatment of heart failure can improve cardiac function and the quality of life of patients.
